Scholars Central

Conference abstractPublished 5 Dec 2016

Insulin resistance reversibility and anti-diabetic potential of isoalantolactone analogues via partial PPAR-γ pathway

Authors: Raj Kirandeep, Sharma Vikram V, Singh Inderjot

Dayanand Medical College and Hospital, Punjab, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Worldwide occurrence of insulin resistance is around 20% of human population and it is primarily linked to type-2 diabetes. Insulin resistance is associated with blunted response of insulin in peripheral tissues like skeletal muscle, adipose tissue and liver. Therapeutic approaches with natural product lay an excellent foundation for search of effective, relatively safe and inexpensive treatment options for diabetes mellitus and associated metabolic disorders in search of novel compound to ameliorate insulin resistance. Peroxisome proliferator-activated receptors (PPAR) are members of the nuclear hormone receptor super-family of ligandactivated transcription factors. PPAR-Ã?³ is the key regulator of lipid metabolism and energy balance implicated in the development of insulin resistance. The identification of putative natural and synthetic ligands and activators of PPAR-Ã?³ has helped to unravel the molecular basis of its function, including molecular details regarding ligand binding, conformational changes of the receptor and cofactor binding leading to the emergence of the concept of selective PPAR-Ã?³ modulators. No satisfactory therapeutic option is currently available to treat patients with nephropathy except for fewer agents like angiotensin converting enzyme inhibitors, angiotensin AT1 receptor blockers and few antioxidants, which have been shown to improve the function of diabetic kidney to some extent. Thus, tremendous efforts are being made to explore promising therapeutic interventions to treat diabetic nephropathy. This review discussed various presently employed and recently developed pharmacological interventions to treat diabetic nephropathy and to improve the function of diabetic kidney. In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalEndocrinology & Metabolic Syndrome
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Raj Kirandeep”
  • BylineArticles whose byline prints “Sharma Vikram V”
  • BylineArticles whose byline prints “Singh Inderjot”